Pulmatrix, Inc. Common Stock (PULM) Stock Price

PULMStock

$1.36−71.42%52W

Market Cap$4.97M

P/E—

PEG Ratio—

Div yield—

Beta1.98

PULM Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)2.49%

Price vs S&P 500 (4W)-17.72%

VGM Score48.01

Book Value / Share (Quarterly)$0.70

P/TBV (Annual)1.01x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)14.72%

Cash Flow / Share (Quarterly)$-1.07

Price vs S&P 500 (YTD)-50.74%

Net Profit Margin (TTM)-122.46%

EPS (TTM)$-1.41

10-Day Avg Trading Volume0.02M

EPS Excl Extra (TTM)$-1.41

Revenue Growth (5Y)-0.26%

EPS (Annual)$-1.41

ROI (Annual)-135.49%

Net Profit Margin (5Y Avg)-233.87%

Cash / Share (Quarterly)$0.59

ROA (Last FY)-124.72%

Revenue Growth TTM (YoY)-99.97%

EBITD / Share (TTM)$-1.42

ROE (5Y Avg)-84.77%

Operating Margin (TTM)-125.07%

Cash Flow / Share (Annual)$-1.49

P/B Ratio1.94x

P/B Ratio (Quarterly)2.43x

Net Income / Employee (Annual)$-2,581,000

EV / Revenue (TTM)0.36x

Net Interest Coverage (TTM)-127.50x

ROA (TTM)-88.53%

EPS Incl Extra (Annual)$-1.41

Current Ratio (Annual)12.55x

Quick Ratio (Quarterly)4.36x

3-Month Avg Trading Volume0.04M

52-Week Price Return-71.42%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$125.14

P/S Ratio (Annual)0.64x

Asset Turnover (Annual)0.79x

52-Week High$5.24

Operating Margin (5Y Avg)-221.49%

EPS Excl Extra (Annual)$-1.41

CapEx CAGR (5Y)46.00%

26-Week Price Return12.40%

Quick Ratio (Annual)12.53x

13-Week Price Return-15.53%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.70x

Enterprise Value$2.80M

Revenue / Share Growth (5Y)-25.66%

Asset Turnover (TTM)0.46x

Book Value / Share Growth (5Y)-39.42%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-122.46%

Cash / Share (Annual)$1.12

3-Month Return Std Dev59.24%

Net Income / Employee (TTM)$-2,581,000

ROE (Last FY)-135.49%

Net Interest Coverage (Annual)-45.32x

EPS Basic Excl Extra (Annual)$-1.41

Receivables Turnover (TTM)6.56x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.41

Receivables Turnover (Annual)16.82x

ROI (TTM)-96.97%

P/S Ratio (TTM)0.64x

Pretax Margin (5Y Avg)-233.87%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$125.14

Price vs S&P 500 (52W)-86.95%

Year-to-Date Return-39.01%

5-Day Price Return-4.90%

EPS Normalized (Annual)$-1.41

ROA (5Y Avg)-68.55%

Net Profit Margin (Annual)-122.46%

Month-to-Date Return-10.53%

Cash Flow / Share (TTM)$-4.42

EBITD / Share (Annual)$-1.42

Operating Margin (Annual)-125.07%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-84.77%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.41

P/TBV (Quarterly)1.01x

P/B Ratio (Annual)2.14x

Pretax Margin (TTM)-122.46%

Book Value / Share (Annual)$1.04

Price vs S&P 500 (13W)-18.21%

Beta1.98x

P/FCF (Annual)1.57x

Revenue / Share (TTM)$0.00

ROE (TTM)-96.97%

52-Week Low$1.16

vGradeA

gGradeF

mGradeC

vgmGradeC

PULM Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2023	Nov 9, 2023	-$1.05	-$1.03	+1.90%(+$0.02)
Q2 2023	Aug 10, 2023	-$1.23	-$1.04	+15.45%(+$0.19)
Q4 2022	Mar 30, 2023	-$1.44	-$1.14	+20.83%(+$0.30)

PULM Analyst Recommendations

Dec 2024

Jan 2025

Feb 2025

Mar 2025

4.14

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PULMPulmatrix, Inc. Common Stock	A	F	C	0.6x	-100.0%	—	—	$1.36
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Pulmatrix, Inc. Common Stock

Pulmatrix is a biopharmaceutical company developing inhaled therapies for migraine and respiratory diseases using its proprietary iSPERSE dry powder delivery platform. Its clinical pipeline includes PUR3100 for acute migraine, PUR1800 for COPD exacerbations, and PUR1900 for aspergillosis in asthma and cystic fibrosis patients, targeting significant unmet medical needs.